Tests rimegepant to prevent menstrual migraine in women
Tests rimegepant against placebo for preventing menstrual migraine attacks in women.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Key facts
- Where
- Ann Arbor, Austin, Aventura, Canoga Park, Centerville, Charlottesville, Colton, Dallas, Durham, East Greenwich, Evansville, Hallandale, Jacksonville, Knoxville, Las Vegas, Marietta, McLean, Meridian, Papillion, Philadelphia, Phoenix, Rochester, Scottsdale, Springfield, Stockbridge, The Bronx, Walnut Creek, and Weldon Spring, United StatesSee the 31 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06641466, who can take part
Where in United States
- Michigan Headache & Neurological InstituteAnn Arbor, United StatesTaking people
- FutureSearch Trials of NeurologyAustin, United StatesTaking people
- VIN - AventuraAventura, United StatesTaking people
- Hope Clinical Research, Inc.Canoga Park, United StatesTaking people
- Dayton Center for Neurological DisordersCenterville, United StatesTaking people
- Charlottesville Medical ResearchCharlottesville, United StatesTaking people
- Axiom ResearchColton, United StatesTaking people
- FutureSearch Trials of DallasDallas, United StatesTaking people
- Carolina Women's Research and Wellness CenterDurham, United StatesTaking people
- Velocity Clinical Research, ProvidenceEast Greenwich, United StatesTaking people
- Alliance for Multispecialty Research - Medisphere Medical Research CenterEvansville, United StatesTaking people
- Velocity Clinical Research, Hallandale BeachHallandale, United StatesTaking people
- Jacksonville Center for Clinical ResearchJacksonville, United StatesTaking people
- Alliance for Multispecialty Research, LLCKnoxville, United StatesTaking people
- AMR ClinicalKnoxville, United StatesTaking people
- Excel Clinical Research, LLCLas Vegas, United StatesTaking people
- Urban Family Practice AssociatesMarietta, United StatesTaking people
- MedStar Health Neurology/MedStar Georgetown Headache CenterMcLean, United StatesTaking people
- St Luke's Clinic - NeurologyMeridian, United StatesTaking people
- McGill Family PracticePapillion, United StatesTaking people
- Clinical Research of PhiladelphiaPhiladelphia, United StatesTaking people
- Thomas Jefferson University, Jefferson Headache CenterPhiladelphia, United StatesTaking people
- Mayo Clinic HospitalPhoenix, United StatesTaking people
- Mayo Clinic Specialty BuildingPhoenix, United StatesTaking people
- Rochester Clinical ResearchRochester, United StatesTaking people
- Mayo Clinic - ArizonaScottsdale, United StatesTaking people
- Clinvest Headlands LLCSpringfield, United StatesTaking people
- Clinical Research AtlantaStockbridge, United StatesTaking people
- Montefiore Medical CenterThe Bronx, United StatesTaking people
- Diablo Clinical Research, Inc.Walnut Creek, United StatesTaking people
- St. Charles Clinical ResearchWeldon Spring, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06641466EU 2024-517121-10-00
- Record updated
- 9 July 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.Read full original descriptionShow less
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Inclusion: Participant has regular menstrual cycles ≥24 days and ≤34 days; A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition; A history of menstrual migraine attacks of at least 3 months; Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening; If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study.
Exclusion: Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening; A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening; History of retinal migraine, basilar migraine or hemiplegic migraine; Current diagnosis of schizophrenia, bipolar, or borderline personality disorder; Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea.